Trials / Completed
CompletedNCT01420068
52-104 Week Off-therapy Second Extension to Study CSPP100A2365
A Multicenter, Double-blind 52 to 104 Week Off-therapy Extension Study to Evaluate the Long Term Growth and Development of Pediatric Hypertensive Patients 6 - 17 Years of Age Previously Treated With Aliskiren in Studies CSPP100A2365 and/or CSPP100A2365E1
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 106 (actual)
- Sponsor
- Noden Pharma · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPP100 |
Timeline
- Start date
- 2011-08-19
- Primary completion
- 2017-08-03
- Completion
- 2017-08-03
- First posted
- 2011-08-19
- Last updated
- 2019-03-19
- Results posted
- 2019-02-15
Locations
25 sites across 7 countries: United States, Guatemala, Hungary, Poland, Puerto Rico, Slovakia, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01420068. Inclusion in this directory is not an endorsement.